Skip To Main Content
Adam Barczyk on Muck Rack

Adam Barczyk

As seen in: MDPI, Thorax, Respiratory Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Adam

Contact Adam, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

2024 Update on Position Statement by Experts from the Polish Society of Allergology and the Polish Respiratory Society on the Evaluation of Efficacy and Effectiveness of Single Inhaler Triple Therapies in Asthma Treatment

|
By Paweł Śliwiński, Adam Antczak, Adam Barczyk, Adam Białas
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

2024 Update on Position Statement by Experts from the Polish Society of Allergology and the Polish Respiratory Society on the Evaluation of Efficacy and Effectiveness of Single Inhaler Triple Therapies in Asthma Treatment

|
By Paweł Śliwiński, Adam Antczak, Adam Barczyk, Adam Białas
| Preprints.org
Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 24 July 2024 / Approved: 25 July 2024 / Online: 26 July 2024 (11:32:02 CEST) Śliwiński, P.; Antczak, A.; Barczyk, A.; Białas, A. J.; Czajkowska-Malinowska, M.; Jahnz-Różyk, K.; Kulus, M.; Kuna, P.; Kupczyk, M.
Open in Who Shared Issue with article?

Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial

|
By Alex West Verified, Nazia Chaudhuri, Adam Barczyk, Margaret L Wilsher
| Thorax Verified
Discussion The ATLAS study shows the potential of aerosolised pirfenidone for improved safety and efficacy compared with oral pirfenidone in treating IPF. Both AP01 doses were well tolerated, and the most common dose-limiting AEs associated with oral pirfenidone22 were reduced or absent. As with oral pirfenidone,23 AEs generally occurred within 3 months.
Open in Who Shared Issue with article?
See all 6 articles